10 The objectives of this article are (1) to provide a description of all adult patients enrolled in NASH CRN studies; (2) to determine the associations of basic clinical variables with the diagnosis of definite NASH, stage of fibrosis, grade of inflammation and presence of hepatocellular ballooning injury; and (3) to determine the overall accuracy of models using only demographic and basic clinical variables to predict the presence find more of NASH,

and the activity grade and fibrosis stage of NASH. A similar analysis of the clinical and histological features of NAFLD in children enrolled in the NASH CRN studies has been published.11 ANA, antinuclear antibody; ASMA, anti-smooth muscle antibody; ANA, antimitochondrial antibody; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC, area under the receiver operator characteristic curve; BMI, body mass index; CI, confidence interval; GGT, gamma glutamyl transpeptidase; HDL, high-density lipoprotein; HOMA-IR, homeostasis model of assessment of insulin resistance; LDL, low-density lipoprotein; NAFLD, nonalcoholic fatty

liver disease; NASH, nonalcoholic steatohepatitis; NASH CRN, NASH Clinical Research Network; NAS, NAFLD activity score; NCEP, National Cholesterol Depsipeptide clinical trial Education Program; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases. Patients with suspected or histologically proven NAFLD were enrolled into the Database observational study at nine U.S. medical centers: Case Western Reserve (Cleveland, OH); Duke University (Durham, NC); Indiana University (Indianapolis, IN); Johns Hopkins University (Baltimore, MD); Saint

Louis University (St. Louis, MO); University of California, San Diego (San Diego, CA); University of California, San Francisco (San Francisco, CA); University of Washington (Seattle, WA); and Virginia Commonwealth University (Richmond, VA). The data were stored, monitored, Adenosine and analyzed at the Data Coordinating Center at the Johns Hopkins Bloomberg School of Public Health. The NASH CRN enrolled into the Database patients who were at least 2 years of age who met any one of the following criteria: (1) a histologic diagnosis of NAFLD; (2) a histologic diagnosis of cryptogenic cirrhosis; (3) suspected NAFLD based on imaging studies; (4) clinical evidence of cryptogenic cirrhosis. Patients were excluded if they had clinical or histological evidence of alcoholic liver disease or alcohol consumption during the 2 years before entry of more than 20 g daily for men and 10 g daily for women.